- $150.07m
- -$111.23m
- $2.85m
Upstream Bio Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle
Brief: Upstream Bio To Showcase Additional Efficacy Data From The Phase 2 Vibrant Trial Of Verekitug In Crswnp In Oral Session At Eaaci 2026
Upstream Bio Q1 net loss widens on higher R&D costs
Upstream Bio Q4 net loss widens on higher R&D costs
Brief: Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score
U.S. STOCKS ON THE MOVE-Micron, McDonald's, Generac
U.S. STOCKS ON THE MOVE-Klaviyo, Frontier Group, Wabtec
U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation Energy
Upstream Bio plunges as asthma drug misses 'home run' bar
U.S. STOCKS ON THE MOVE-McDonald's, Cloudflare, Gold miners
Upstream Bio jumps as experimental asthma drug shows promise in mid‑stage study
Brief: Upstream Bio Reports Positive Top-Line Results From The Phase 2 Valiant Trial Of Verekitug For The Treatment Of Severe Asthma
U.S. RESEARCH ROUNDUP- Autozone, Coursera, Lennar
Brief: Upstream Bio Reports Positive Top-Line Results From The Phase 2 Vibrant Trial Of Verekitug For The Treatment Of Chronic Rhinosinusitis With Nasal Polyps (Crswnp)
Brief: Upstream Bio Announces First Patient Dosed In Phase 2 Clinical Trial Of Verekitug
Brief: Upstream Bio Reports Q3 2024 Financial Results And Recent Business Highlights
Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO (updated)
Upstream Bio jumps in market debut